Intraportal donor bone marrow transplantation improves intestinal allograft survival in rats under FK506-based immunosuppression

Journal of International Medical Research

Volumn 31, Issue 4, 2003, Pages 281-289

  Sun, D S ^a   Yagi, T ^a   Oyama, T ^a   Matsukawa, H ^a   Matsuda, H ^a   Sadamori, H ^a   Inagaki, M ^a   Matsuoka, J ^a   Iwagaki, H ^a   Tanaka, N ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Bone marrow transplantation; FK506; Interferon (IFN) ; Interleukin (IL) 2; Small bowel transplantation; Steroids

Indexed keywords

BETA ACTIN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 2; PREDNISOLONE; TACROLIMUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; DONOR; DOWN REGULATION; GENETIC TRANSCRIPTION; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HETEROTOPIC TRANSPLANTATION; IMMUNE DEFICIENCY; INTERMETHOD COMPARISON; INTESTINE GRAFT; INTESTINE TRANSPLANTATION; LOW DRUG DOSE; NONHUMAN; POSTOPERATIVE PERIOD; PREOPERATIVE CARE; PROTEIN EXPRESSION; RAT; RAT STRAIN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

EID: 10744228624     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000303100405     Document Type: Article

References (30)

1. Schraut WH: Current status of small bowel transplantation. Gastroenterology 1988; 94: 525 - 533.
2. Tzakis AG, Todo S, Reyes J, Nour B, Abu-Elmagd K, Selby R, et al: Intestinal transplantation in children under FK506 immunosuppression. J Pediatr Surg 1993; 28: 1040 - 1043.
3. Murase N, Demetris AJ, Woo J, Tanabe M, Furuya T, Todo S, et al: Graft-versus-host disease after Brown Norway-to-Lewis and Lewis-to-Brown Norway rat intestinal transplantation under FK506. Transplantation 1993; 55: 1 - 7.
4. Reyes J, Bueno J, Kocoshis S, Green M, Abu-Elmagd K, Furukawa H et al: Current status of intestinal transplantation in children. J Pediatr Surg 1998; 33: 243 - 254.
5. Todo S, Tzakis AG, Abu-Elmagd K, Reyes J, Fung JJ, Casavilla A et al: Cadaveric small bowel and small bowel/liver transplantation in humans. Transplantation 1992; 53: 369 - 376.
6. Todo S, Tzakis A, Abu-Elmagd K, Reyes J, Starzl TE: Current status of intestinal transplantation. Adv Surg 1994; 27: 295 - 316.
7. Gruessner R, Sharp HL: Living-related intestinal transplantation: first report of a standardized surgical technique. Transplantation 1997; 64: 1605 - 1607.
8. Madsen KL, Yanchar NL, Sigalet DL, Reigel T, Fedorak RN: FK506 increases permeability in the intestine by inhibiting mitochondrial function. Gastroenterology 1995; 109: 107 - 114.
9. Sigalet DL, Williams DC, Garola R, Thorne P, Martin G: Impact of FK506 and steroids on adaptation after intestinal resection or segmental transplantation. Pediatr Transplant 2000; 4: 12 - 20.
10. Fauci AS: Immunosuppressive and antiinflammatory effects of glucocorticoids. In: Glucocorticoid Hormone Action (Baxter JG, Rousseau G, eds). New York: Springer Publishing Co Inc., 1979; pp449 - 465.
11. Beato M: Gene regulation by steroid hormones. Cell 1989; 56: 335 - 344.
12. Nakao A, Kobayashi E, Shen SD, Yoshino T, Tanaka N: Impact of tacrolimus and bone marrow augmentation on intestinal allograft survival and intragraft cytokine expression. J Med 2001; 32: 207 - 230.
13. Kobayashi E, Kamada N, Enosawa S, Toyama N, Delriviere L, Goto S, et al: Comparison of potentiality to induce graft-versus-host reaction with small bowel, pancreas/spleen, and liver transplantation in the rat. Clin Exp Immunol 1993; 92: 527 - 531.
14. Lerut JP, Ciccarelli O, Mauel E, Gheerardhyn R, Talpe S, Sempoux C, et al: Adult liver transplantation and steroid-azathioprine withdrawal in cyclosporine-based immunosuppression - 5 year results of a prospective study. Transpl Int 2001; 14: 420 - 428.
15. Nakano Y, Monden M, Valdivia LA, Gotoh M, Tono T, Mori T. Permanent acceptance of liver allografts by intraportal injection of donor spleen cells in rats. Surgery 1992; 111: 668 - 676.
16. Yoshimura N, Matsui S, Hamashima T, Lee CJ, Ohsaka Y, Oka T. The effects of perioperative portal venous inoculation with donor lymphocytes on renal allograft survival in the rat. I. Specific prolongation of donor grafts and suppressor factors in the serum. Transplantation 1990; 49: 167 - 171.
17. Gorczynski RM, Chan Z, Chung S, Cohen Z, Levy G, Sullivan B, et al: Prolongation of rat small bowel or renal allograft survival by pretransplant transfusion and/or by varying the route of allograft venous drainage. Transplantation 1994; 58: 816 - 820.
18. Sugiura K, Kato K, Hashimoto F, Jin T, Amoh Y, Yamamoto Y, et al: Induction of donor-specific T cell anergy by portal venous injection of allogenic cells. Immunobiology 1997; 197: 460 - 477.
19. Perez RV, Swanson C, Morgan M, Erickson K, Hubbard NE, German JB: Portal venous transfusion upregulates Kupffer cell cyclooxygenase activity: a mechanism of immunosuppression in organ transplantation. Transplantation 1997; 64: 135 - 139.
20. Gorczynski RM, Chen Z, Hoang Y, Rossi-Bergman B: A subset of gamma delta T-cell receptor-positive cells produce T-helper type-2 cytokines and regulate mouse skin graft rejection following portal venous pretransplant preimmunization. Immunology 1996; 87: 381 - 389.
21. Ishido N, Matsuoka J, Matsuno T, Nakagawa K, Tanaka N: Induction of donor-specific hyporesponsiveness and prolongation of cardiac allograft survival by jejunal administration of donor splenocytes. Transplantation 1999; 68: 1377 - 1382.
22. McDiarmid SV, Farmer DG, Kuniyoshi JS, Robert M, Khadavi A, Shaked A, et al: The correlation of intragraft cytokine expression with rejection in rat small intestine transplantation. Transplantation 1994; 58: 690 - 697.
23. Madara JL, Stafford J: Interferon-gamma directly affects barrier function of cultured intestinal epithelial monolayers. J Clin Invest 1989; 83: 724 - 727.
24. Su GL, Walgenbach KJ, Heeckt PH, Wang Q, Halfter W, Whiteside TL, et al: Increased expression of interferon-gamma in a rat model of chronic intestinal allograft rejection. Transplantation 1996; 62: 242 - 248.
25. Nathan CF, Murray HW, Wiebe ME, Rubin BY: Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med 1983; 158: 670 - 689.
26. Yamamoto M, Fujihashi K, Beagley KW, McGhee JR, Kiyono H: Cytokine synthesis by intraepithelial lymphocytes. Both gamma/delta T cell receptor-positive and alpha/beta T cell receptor-positive T cells in the G1 phase of cell cycle produce IFN-gamma and IL-5. J Immunol 1993; 150: 106 - 114.
27. Monaco AP: Strategies for induction of clinical tolerance. Transplant Proc 2001; 33: 51 - 56.
28. Levy AE, Alexander JW: The significance of timing of additional short-term immunosuppression in the donor-specific transfusion/cyclosporine-treated rat. Transplantation 1996; 62: 262 - 266.
29. Conti F, Dousset B, Archambeau D, Louvel A, Houssin D, Calmus Y: Enhanced risk of steroid-resistant acute rejection following pretransplant steroid therapy in liver graft recipients. Transplantation 1995; 60: 1104 - 1108.
30. Koshiba T, Van Damme B, Ji P, Lu Y, Sefrioui H, Overbergh L, et al: Addition of steroids blocks the tolerogenic potential of donor-specific blood transfusion. Transplant Proc 2001; 33: 375 - 376.